Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015

Birgitte K Giersing; Kayvon Modjarrad; David C Kaslow; Vasee S Moorthy; WHO Product Development for Vaccines Advisory Committee; WHO Product Development for Vaccines Product Development Advisory Committee:

doi:10.1016/j.vaccine.2016.02.078

Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015

Vaccine. 2016 Jun 3;34(26):2865-2869. doi: 10.1016/j.vaccine.2016.02.078. Epub 2016 Mar 15.

Authors

Birgitte K Giersing¹, Kayvon Modjarrad², David C Kaslow³, Vasee S Moorthy⁴; WHO Product Development for Vaccines Advisory Committee; WHO Product Development for Vaccines Product Development Advisory Committee:

Collaborators

Ashish Bavdekar⁵, Klaus Cichutek⁶, Alejandro Cravioto⁷, Bernard Fritzell⁸, Barney S Graham⁹, Ruth Karron¹⁰, Claudio F Lanata¹¹, Mair Powell¹², Yiming Shao¹³, Peter Smith¹⁴

Affiliations

¹ Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.
² US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
³ PATH, Seattle, WA 98109, USA.
⁴ Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address: moorthyv@who.int.
⁵ Kem Hospital and Research Center, Pune, India.
⁶ Paul-Ehrlich-Institut, Langen, Germany.
⁷ Global Evaluative Sciences Inc., Seattle, WA, USA.
⁸ Independent Consultant, Bordeaux, France.
⁹ National Institutes of Health, Bethesda, MD, USA.
¹⁰ Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
¹¹ Instituto de Investigacion Nutricional, Lima, Peru; US Naval Medical Research Unit No. 6, Callao, Peru.
¹² Medicines and Healthcare Products Regulatory Agency, London, United Kingdom of Great Britain & Northern Ireland.
¹³ Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
¹⁴ London School of Hygiene and Tropical Medicine, London, United Kingdom of Great Britain & Northern Ireland.

Abstract

There are more vaccines in development, against a greater number of pathogens, than ever before. A challenge with this exceptional level of activity and investment is how to select and resource the most promising approaches to have the most significant impact on public health. The WHO Product Development for Vaccines Advisory Committee (PDVAC) was established in 2014 to provide strategic advice and recommendations to WHO for vaccines in clinical development that could have a significant impact on public health in low and middle income countries. On 7-9th September 2015, PDVAC was convened for the second time, when the committee reviewed vaccine developments in 24 disease areas. This report summarises the key recommendations from that consultation.

Keywords: Candidate; LMIC; PPC; Product development; Vaccine.

MeSH terms

Advisory Committees*
Biomedical Research
Communicable Disease Control
Global Health
Humans
Switzerland
Vaccination / trends*
Vaccines / therapeutic use*
World Health Organization*

Substances

Vaccines

Grants and funding

001/WHO_/World Health Organization/International